Table 2 Characteristics in the IDH-wildtype glioblastoma patients without and with GC

Age (year)

61.7 (53.0–69.0)

62.0 (35.6–77.7)

60.0 (32.5–77.4)

0.070

Sex (female)

330 (40.4)

300 (40.5)

30 (39.0)

0.788

KPS

80 (70–90)

80 (50–100)

80 (40–90)

0.337

Histological grade 2 or 3 (Molecular glioblastoma)

40 (4.9)

28 (3.8)

12 (15.6)

< 0.001

Molecular markers

   MGMT promoter methylation

294 (36.0)

271 (36.6)

23 (29.9)

0.240

   TERTp mutation, present/tested

308/613 (50.2)

280/558 (50.2)

28/55 (50.9)

0.918

   EGFR amplification, present/tested

184/617 (29.8)

170/559 (30.4)

14/58 (24.1)

0.320

   + 7/-10, present/tested^,

66/294 (22.4)

63/268 (23.5)

3/26 (11.5)

0.163

   TP53 mutation, present/tested^,

140/613 (22.8)

126/558 (22.6)

14/55 (25.5)

0.628

   ATRX loss, present/tested

81/748 (10.8)

67/674 (9.9)

14/74 (18.9)

0.018

   p53 protein expression

121/594 (20.4)

109/537 (20.3)

12/57 (21.1)

0.893

MRI findings

   Infratentorial location

32 (3.9)

29 (3.9)

3 (3.9)

0.992

   Presence of contrast enhancement

781 (95.6)

712 (96.2)

69 (89.6)

0.001

   Presence of necrosis

564 (69.0)

502 (67.8)

62 (80.5)

0.022

Leptomeningeal metastases

194 (23.7)

178 (24.1)

16 (20.8)

0.520

EOR of entire tumor

< 0.001

   GTR

308 (37.7)

308 (41.6)

0 (0)

   Non-GTR

507 (62.1)

430 (58.1)

77 (100)

Death

580 (71.0)

524 (70.8)

56 (72.7)

0.724

Median OS (month)

17.9 (16.7–19.1)

18.6 (17.3–20.0)

14.2 (11.9–16.4)

0.002